BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36150916)

  • 1. The role of CTNNB1 mutations and matrix metalloproteinases (MMPs) in anti-angiogenesis treatment of endometrial carcinoma.
    Berger AA; Kawaler EA; Dao F; Misirlioglu S; Fernandez EA; Olvera N; Van Oudenhove E; DeLair D; Levine DA
    Gynecol Oncol; 2022 Nov; 167(2):323-333. PubMed ID: 36150916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibiting Wnt/beta-catenin in CTNNB1-mutated endometrial cancer.
    Moroney MR; Woodruff E; Qamar L; Bradford AP; Wolsky R; Bitler BG; Corr BR
    Mol Carcinog; 2021 Aug; 60(8):511-523. PubMed ID: 34038589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nuclear β-catenin localization and mutation of the CTNNB1 gene: a context-dependent association.
    Kim G; Kurnit KC; Djordjevic B; Singh C; Munsell MF; Wang WL; Lazar AJ; Zhang W; Broaddus R
    Mod Pathol; 2018 Oct; 31(10):1553-1559. PubMed ID: 29795437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CTNNB1 mutations and beta-catenin expression in endometrial carcinomas.
    Machin P; Catasus L; Pons C; Muñoz J; Matias-Guiu X; Prat J
    Hum Pathol; 2002 Feb; 33(2):206-12. PubMed ID: 11957146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High Glucose Promotes Epithelial-Mesenchymal Transition of Uterus Endometrial Cancer Cells by Increasing ER/GLUT4-Mediated VEGF Secretion.
    Gu CJ; Xie F; Zhang B; Yang HL; Cheng J; He YY; Zhu XY; Li DJ; Li MQ
    Cell Physiol Biochem; 2018; 50(2):706-720. PubMed ID: 30308493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathologic and Immunohistochemical Correlates of CTNNB1 Mutated Endometrial Endometrioid Carcinoma.
    Costigan DC; Dong F; Nucci MR; Howitt BE
    Int J Gynecol Pathol; 2020 Mar; 39(2):119-127. PubMed ID: 30702464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer.
    Kamat AA; Merritt WM; Coffey D; Lin YG; Patel PR; Broaddus R; Nugent E; Han LY; Landen CN; Spannuth WA; Lu C; Coleman RL; Gershenson DM; Sood AK
    Clin Cancer Res; 2007 Dec; 13(24):7487-95. PubMed ID: 18094433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological features and prognostic significance of CTNNB1 mutation in low-grade, early-stage endometrial endometrioid carcinoma.
    Ruz-Caracuel I; López-Janeiro Á; Heredia-Soto V; Ramón-Patino JL; Yébenes L; Berjón A; Hernández A; Gallego A; Ruiz P; Redondo A; Peláez-García A; Mendiola M; Hardisson D
    Virchows Arch; 2021 Dec; 479(6):1167-1176. PubMed ID: 34420090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study.
    Leslie KK; Filiaci VL; Mallen AR; Thiel KW; Devor EJ; Moxley K; Richardson D; Mutch D; Secord AA; Tewari KS; McDonald ME; Mathews C; Cosgrove C; Dewdney S; Casablanca Y; Jackson A; Rose PG; Zhou X; McHale M; Lankes H; Levine DA; Aghajanian C
    Gynecol Oncol; 2021 Apr; 161(1):113-121. PubMed ID: 33541735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CTNNB1 Mutations and Aberrant β-Catenin Expression in Ovarian Endometrioid Carcinoma: Correlation With Patient Outcome.
    Zyla RE; Olkhov-Mitsel E; Amemiya Y; Bassiouny D; Seth A; Djordjevic B; Nofech-Mozes S; Parra-Herran C
    Am J Surg Pathol; 2021 Jan; 45(1):68-76. PubMed ID: 32769429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sex steroid-dependent angiogenesis in uterine endometrial cancers.
    Fujimoto J; Toyoki H; Jahan I; Alam SM; Sakaguchi H; Sato E; Tamaya T
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):161-5. PubMed ID: 15860258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evodiamine exerts anti-tumor effects against hepatocellular carcinoma through inhibiting β-catenin-mediated angiogenesis.
    Shi L; Yang F; Luo F; Liu Y; Zhang F; Zou M; Liu Q
    Tumour Biol; 2016 Sep; 37(9):12791-12803. PubMed ID: 27449032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer.
    Loizzi V; Del Vecchio V; Gargano G; De Liso M; Kardashi A; Naglieri E; Resta L; Cicinelli E; Cormio G
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28906427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOXF1 promotes angiogenesis and accelerates bevacizumab resistance in colorectal cancer by transcriptionally activating VEGFA.
    Wang S; Xiao Z; Hong Z; Jiao H; Zhu S; Zhao Y; Bi J; Qiu J; Zhang D; Yan J; Zhang L; Huang C; Li T; Liang L; Liao W; Ye Y; Ding Y
    Cancer Lett; 2018 Dec; 439():78-90. PubMed ID: 30253191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ginkgo biloba exocarp extracts inhibits angiogenesis and its effects on Wnt/β-catenin-VEGF signaling pathway in Lewis lung cancer.
    Han D; Cao C; Su Y; Wang J; Sun J; Chen H; Xu A
    J Ethnopharmacol; 2016 Nov; 192():406-412. PubMed ID: 27649680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical Nuclear Expression of β-Catenin as a Surrogate of CTNNB1 Exon 3 Mutation in Endometrial Cancer.
    Travaglino A; Raffone A; Saccone G; De Luca C; Mollo A; Mascolo M; De Placido G; Insabato L; Zullo F
    Am J Clin Pathol; 2019 Apr; 151(5):529-538. PubMed ID: 30715091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of carbonic anhydrase potentiates bevacizumab treatment in cholangiocarcinoma.
    Vaeteewoottacharn K; Kariya R; Dana P; Fujikawa S; Matsuda K; Ohkuma K; Kudo E; Kraiklang R; Wongkham C; Wongkham S; Okada S
    Tumour Biol; 2016 Jul; 37(7):9023-35. PubMed ID: 26762407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
    Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
    Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of differential gene expression in adrenocortical tumors harboring beta-catenin (CTNNB1) mutations.
    Durand J; Lampron A; Mazzuco TL; Chapman A; Bourdeau I
    J Clin Endocrinol Metab; 2011 Jul; 96(7):E1206-11. PubMed ID: 21565795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma.
    Liu Y; Patel L; Mills GB; Lu KH; Sood AK; Ding L; Kucherlapati R; Mardis ER; Levine DA; Shmulevich I; Broaddus RR; Zhang W
    J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25214561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.